Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

8-azaprostaglandin derivatives and medical use thereof

a technology of azaprostaglandin and derivatives, applied in the field of 8azaprostaglandin derivatives, can solve the problems of limited safety of dose administration, and achieve the effects of enhancing the preventive and/or treatment

Inactive Publication Date: 2008-02-07
ONO PHARMA CO LTD
View PDF4 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention relates to a compound (Formula I) that specifically binds to the EP4 receptor and has minimal side effects when administered systemically. This compound has been found to have strong agonistic activity and can be used as a drug for the treatment of diseases associated with bone loss, such as osteoporotic bone disease. The compound can be administered topically and can be formulated as a sustained release formulation for long-term treatment. The invention also includes a method for identifying other compounds that can also specifically bind to the EP4 receptor and have minimal side effects. These compounds can be used as drugs for the treatment of diseases associated with bone loss.

Problems solved by technology

Therefore, there was large problem that the dosage capable of safety administration is limited.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • 8-azaprostaglandin derivatives and medical use thereof
  • 8-azaprostaglandin derivatives and medical use thereof
  • 8-azaprostaglandin derivatives and medical use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

(4R,5E)-4-tert-butoxycarbonylamino-7-oxo-8-(3,5-dimethylphenyl)oct-5-enoic acid ethyl ester

[0396] Under atmosphere of argon, a suspension of 60% sodium hydride (50 mg) was added by a solution of dimethyl (2-oxo-3-(3,5-dimethylphenyl)propyl)phosphonate (373 mg) in tetrahydrofuran (5 mL) at the temperature of 0° C. The mixture was stirred for an hour and then a solution of ethyl (4R)-4-(tert-butoxycarbonylamino)-4-formylbutanoate (298 mg) in tetrahydrofuran (5 mL) was added to the mixture. The mixture was stirred for an hour. To the mixture, methyl tert-butyl ether and water were added, and then IN a solution of sodium hydroxide was added. The organic layer was washed with saturated brine, dried over an anhydrous magnesium sulfate, concentrated and was purified by column chromatography on silica gel (hexane:ethyl acetate=4:1) to give the title compound (300 mg) having the following physical data.

[0397] TLC: Rf0.76 (hexane:ethyl acetate=1:1)

example 2

(4R,5E,7S)-4-tert-butoxycarbonylamino-7-hydroxy-8-(3,5-dimethylphenyl)oct-5-enoic acid ethyl ester

[0398] Under atmosphere of argon, a solution of the compound prepared in Example 1 (295 mg) in tetrahydrofuran (7.3 mL) was added by 1.0 mol / l (R)-2-methyl-CBS-oxazaborolidine / toluene solution (0.22 mL) at the temperature of 0° C. Then 1.0 mol / l borane tetrahydrofuran complex / tetrahydrofuran solution was dropped to the mixture, and then the mixture was stirred for 45 minutes. Additionally, 1.0 mol / l (R)-2-methyl-CBS-oxazaborolidine / toluene solution (0.22 mL) and 1.0 mol / l borane tetrahydrofuran complex / tetrahydrofuran solution were dropped to the mixture and then the mixture was stirred for 20 minutes at a temperature of 0° C. To the mixture, small quantity of ethanol and water was added and raised till room temperature. The mixture was extracted with ethyl acetate. The organic layer was washed with diluted hydrochloric acid, saturated sodium bicarbonate water and saturated brine succe...

example 3

(4R,5E,7S)-4-amino-7-hydroxy-8-(3,5-dimethylphenyl)oct-5-enoic acid ethyl ester hydrochloride

[0401]

[0402] A solution of the compound prepared in Example 2 (243 mg) in ethanol (1 mL) was dropped by 4N hydrochloride / dioxane (0.5 mL) at a temperature of 0° C. and the mixture was stirred for 3 hours at room temperature. The mixture was concentrated to give the title compound (205 mg) having the following physical data. The compound was not purified any more and as is to be used in the next reaction.

[0403] TLC: Rf0.29 (chloroform:methanol:acetic acid=9:1:0.1);

[0404] NMR: δ 6.83, 5.90, 5.54, 4.40-4.34, 4.14, 3.76-3.68, 2.82-2.67, 2.27, 2.26, 2.10-1.94, 1.85-1.72, 1.26

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
temperatureaaaaaaaaaa
Login to View More

Abstract

The pharmaceutical composition comprising the compound of the invention having 8-azaprostaglandin skeleton represented by formula (I) (wherein, all the symbols have the same meanings as that of the specification.) a salt thereof, a solvate thereof or a cyclodextrin clathrate thereof, or a prodrug thereof and them as active ingredient have EP4 agonistic action and thus are considered useful for the prevention and / or treatment of immunological diseases, asthma, neuronal cell death, arthritis, lung failure, pulmonary fibrosis, pulmonary emphysema, bronchitis, chronic obstructive pulmonary disease, liver damage, acute hepatitis, nephritis, renal insufficiency, hypertension, myocardial ischemia, systemic inflammatory response syndrome, sepsis, hemophagous syndrome, macrophage activation syndrome, Still's disease, Kawasaki disease, burn, systemic granulomatosis, ulcerative colitis, Crohn's disease, hypercytokinemia at dialysis, multiple organ failure, shock and glaucoma, etc. Furthermore, the compounds also have an action of accelerating bone formation, so it is expected to be useful for the prevention and / or treatment of diseases associated with loss in bone mass, for example, primary osteoporosis, secondary osteoporosis, bone metastasis of cancer, hypercalcemia, Paget's disease, bone loss, osteonecrosis, bone formation after bone operation, alternative treatment for bone grafting.

Description

[0001] This application is a divisional of pending U.S. application Ser. No. 10 / 542,724 (Confirmation No. 5408) filed Jul. 20, 2005, which is a National Stage application of PCT Application No. PCT / JP04 / 00419, filed Jan. 20, 2004, which claims priority of Japanese Patent Application Nos. JP 2003-011936, filed Jan. 21, 2003, and JP 2003-289954, filed Aug. 8, 2003, the disclosure of each of which is incorporated herein by reference in its entirety.FIELD OF THE INVENTION [0002] The present invention relates to the compounds having 8-azaprostaglandin skeleton useful for pharmaceuticals and the pharmaceutical composition comprising them as an active ingredient. BACKGROUND OF THE INVENTION [0003] Prostaglandin E2 (abbreviated as PGE2) has been known as a metabolite in the arachidonate cascade. It has been known that PGE2 possesses cyto-protective activity, uterine contractive activity, a pain-inducing effect, a promoting effect on peristaltic movement, an awakening effect, a suppressive e...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K31/41A61K31/4015C07D207/18C07D257/04A61P1/04A61P1/16A61P9/00A61P9/12A61P11/00A61P11/06A61P13/12A61P19/02A61P19/10A61P27/06A61P29/00A61P37/02A61P43/00C07D417/12C07D417/14
CPCC07D417/14C07D417/12A61P1/02A61P1/04A61P1/06A61P1/16A61P3/14A61P7/06A61P9/00A61P9/10A61P9/12A61P11/00A61P11/06A61P13/00A61P13/12A61P15/00A61P15/06A61P15/10A61P17/14A61P19/02A61P19/08A61P19/10A61P21/02A61P25/00A61P25/28A61P27/06A61P29/00A61P31/04A61P37/00A61P37/02A61P37/06A61P43/00
Inventor KAMBE, TOHRUMARUYAMA, TORUKOBAYASHI, KAORUTANI, KOUSUKENAKAI, YOSHIHIKONAGASE, TOSHIHIKOMARUYAMA, TAKAYUKISAKATA, KIYOTOYOSHIDA, HIDEYUKIFUJIMURA, SHINSEINISHIURA, AKIOABE, NOBUTAKA
Owner ONO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com